醫(yī)療特長（限400字內(nèi)）：
熟練掌握各個系統(tǒng)常規(guī)標(biāo)本,、冰凍標(biāo)本病理診斷技術(shù)，專長于淋巴造血系統(tǒng)腫瘤和骨髓病理診斷
研究方向：
骨肉瘤發(fā)生發(fā)展以及侵襲轉(zhuǎn)移機(jī)制的研究
主要教育和工作經(jīng)歷：
1994年畢業(yè)于河南醫(yī)科大學(xué)臨床醫(yī)療系獲醫(yī)學(xué)學(xué)士,； 1998年畢業(yè)于中山醫(yī)科大學(xué)基礎(chǔ)醫(yī)學(xué)院病理學(xué)專業(yè)獲醫(yī)學(xué)碩士,；2004年畢業(yè)于中山大學(xué)病理學(xué)與病理生理學(xué)專業(yè)獲醫(yī)學(xué)博士；1998年至2006年任中山醫(yī)科大學(xué)中山醫(yī)院病理學(xué)教研/附屬第一醫(yī)院病理科助教,、講師,；2007年至2014年任中山大學(xué)附屬第一醫(yī)院病理科副教授；2009年至2011年在美國德克薩斯大學(xué)MD Anderson Cancer Center從事博士后研究工作兩年,；2015年起任中山大學(xué)附屬第一醫(yī)院病理科主任醫(yī)師,。2007年起聘為碩士研究生導(dǎo)師。
社會兼職：
現(xiàn)任廣東省醫(yī)學(xué)會病理學(xué)分會第十屆委員會常務(wù)委員,；中國抗癌協(xié)會腫瘤病理專業(yè)委員會青年委員會委員,；廣東省抗癌協(xié)會腫瘤病理專業(yè)委員會委員；廣東省醫(yī)療行業(yè)協(xié)會病理醫(yī)學(xué)管理分會委員
論著：
共發(fā)表論文40余篇,，已發(fā)表SCI論文20篇,。主持國自然、教育部留學(xué)回國人員基金,、省自然等科研基金項目5項,，作為主要參與人參與科研基金7項。主編或參編《病理學(xué)》教材/專著8部,。
SCI論文：
1.Tian R, Xie X, Han J, Luo C, Yong B, Peng H, Shen J, Peng T. miR-199a-3p negatively regulates the progression of osteosarcoma through targeting AXL American Journal of Cancer Research. 2014;4(6):738-750.
2.Han J, Tian R, Yong B, Luo C, Tan P, Shen J, Peng T. Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients. Biochem Biophys Res Commun. 2013 Jun 7;435(3):493-500.
3.Han J, Yong B, Luo C, Tan P, Peng T, Shen J. High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern China. World J Surg Oncol. 2012 Feb 15;10:37.
4.Cao Q, Huang Y, Ye Z, Liu N, Li S, Peng T. Primary spleen extranodal NK/T cell lymphoma, nasal type, with bone marrow involvement and CD30 positive expression: a case report and literature review. Diagn Pathol. 2014 Sep 3;9(1):169.
5.Shi H, Han J, Liu N, Ye Z, Li Z, Li Z, Peng T. A gangliocytic patially glandular paraganglioma with lymph node metastasis. Diagn Pathol. 2014 Mar 20;9:63.
6.Xu Q, Cao Q, Liu N, Fang Z, Ye Z, Peng T. Renal collecting duct carcinoma with extensive coagulative necrosis mimicking anemic infarct: report of a case and the literature review. Diagn Pathol. 2013 Jul 16;8(1):119.
7.Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, Young ED, Wang X, Brewer K, López-Terrada DH, Oliveira AM, Lazar AJ, Lev D. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest. 2011 Mar;91(3):392-403.
8.Zhang Y, Young ED, Bill K, Belousov R, Peng T, Lazar AJ, Pollock RE, Simmons PJ, Lev D, Kolonin MG. Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas. Stem Cell Res. 2013 Sep;11(2):772-81.
9.Hoffman A, Ghadimi MP, Demicco EG, Creighton CJ, Torres K, Colombo C, Peng T, Lusby K, Ingram D, Hornick JL, Wang WL, Ravi V, Lazar AJ, Lev D, Pollock RE. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. Cancer. 2013 May 15;119(10):1868-77.
10.Tan P, Zou C, Yong B, Han J, Zhang L, Su Q, Yin J, Wang J, Huang G, Peng T, Shen J. Expression and prognostic relevance of PRAME in primary osteosarcoma. Biochem Biophys Res Commun. 2012 Mar 23;419(4):801-8.
11.Zhang P, Bill K, Liu J, Young E, Peng T, Bolshakov S, Hoffman A, Song Y, Demicco EG, Terrada DL, Creighton CJ, Anderson ML, Lazar AJ, Calin GG, Pollock RE, Lev D. MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling. Cancer Res. 2012 Apr 1;72(7):1751-62.
12.Demicco EG, Torres KE, Ghadimi MP, Colombo C, Bolshakov S, Hoffman A, Peng T, Bovée JV, Wang WL, Lev D, Lazar AJ. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol. 2012 Feb;25(2):212-21.
13.Xie X, Ghadimi MP, Young ED, Belousov R, Zhu QS, Liu J, Lopez G, Colombo C, Peng T, Reynoso D, Hornick JL, Lazar AJ, Lev D. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res. 2011 Sep 15;17(18):5901-12.
14.Ghadimi MP, Al-Zaid T, Madewell J, Peng T, Colombo C, Hoffman A, Creighton CJ, Zhang Y, Zhang A, Lazar AJ, Pollock RE, Lev D. Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis. Ann Surg Oncol. 2011 Dec;18(13):3762-70.
15.Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, Torres KE, Colombo C, Hoffman A, Broccoli D, Hornick JL, Lazar AJ, Pisters P, Pollock RE, Lev D. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011 Dec 1;117(23):5359-69.
16.Ye Z, Shi H, Peng T, Han A. Clinical and pathological features of high grade primary cardiac osteosarcoma. Interact Cardiovasc Thorac Surg. 2011 Jan;12(1):94-5.
17.Wang A, Liu X, Sheng S, Ye H, Peng T, Shi F, Crowe DL, Zhou X. Dysregulation of heat shock protein 27 expression in oral tongue squamous cell carcinoma. BMC Cancer. 2009 Jun 4;9:167.
18.Ye H, Wang A, Lee BS, Yu T, Sheng S, Peng T, Hu S, Crowe DL, Zhou X. Proteomic based identification of manganese superoxide dismutase 2 (SOD2) as a metastasis marker for oral squamous cell carcinoma. Cancer Genomics Proteomics. 2008 Mar-Apr;5(2):85-94.
19.Wang L, Li HG, Wen JM, Peng TS, Zeng H, Wang LY. Expression of CD44v3, erythropoietin and VEGF-C in gastric adenocarcinomas: correlations with clinicopathological features. Tumori. 2014 May-Jun;100(3):321-327
20.Wang L, Li HG, Xia ZS, Lü J, Peng TS. IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study. Chin Med J (Engl). 2010 Dec;123(24):3554-8.
